Stomach Cancer
Stomach cancer in brief
Stomach cancer is a common cancer in Germany: around 15,000 people develop it every year. In women it is the ninth most common cancer, in men the tenth most common. Stomach cancer mainly affects older people; the median age at diagnosis is about 70. Men are affected almost twice as often as women. Despite advances in treatment, stomach cancer is a serious disease: about two thirds of those affected die within five years of diagnosis. If it is detected early, however, the chances of a cure are considerably better.
Stomach cancer at a glance
- New cases in Germany
- Around 15,000 per year
- Typical age
- Median age at diagnosis about 70; men affected almost twice as often as women
- Most common form
- Adenocarcinoma (about 90 % of malignant tumors in the stomach)
- Most important risk factor
- Infection of the stomach lining with the bacterium Helicobacter pylori
What exactly is stomach cancer?
The stomach contains different cells, each with specific tasks. The most common form of stomach cancer arises from the glandular cells of the stomach lining. Healthy glandular cells produce, for example, stomach acid and mucus, which protects the stomach wall. Cancer that arises from glandular cells is called adenocarcinoma. Since about 90 % of malignant tumors in the stomach are adenocarcinomas, this article refers to this group.
Why do I have stomach cancer?
There is no single cause for the development of stomach cancer. However, a number of risk factors are known, which can be divided into hereditary and acquired risk factors.
Hereditary or congenital risk factors include:
- First-degree relatives with stomach cancer
- Male sex
- Blood group A and
- Rare genetic syndromes such as Lynch syndrome (HNPCC) or hereditary diffuse gastric cancer (a change in the CDH1 gene)
Acquired risk factors include:
- An infection of the stomach lining with the bacterium Helicobacter pylori – the most important risk factor
- Dietary factors such as a high intake of salt-preserved foods (e.g. cured meats), a lot of processed meat, and a low intake of fruit and vegetables
- Smoking
- Chronic inflammation of the stomach lining (atrophic gastritis) and reflux (backflow of stomach acid into the esophagus, especially for tumors at the entrance to the stomach)
- Overweight, especially around the abdomen
Although these factors can increase the risk, this does not mean that every person with these risk factors will inevitably develop stomach cancer.
Symptoms of stomach cancer
In very early stages, stomach cancer often causes no symptoms. In advanced stomach cancer and/or when it has already spread to other organs, the following symptoms may occur:
- Difficulty swallowing (with tumors at the entrance to the stomach)
- Pain in the upper abdomen
- Repeated vomiting
- Little or no appetite and feeling full early
- Weight loss
- Bleeding in the gastrointestinal tract: this can show up, for example, as very dark, tarry stools or as anemia
- Unexplained vitamin B12 deficiency: this is usually noticed in lab tests. A factor needed to absorb vitamin B12 is produced in the stomach. If the function of the stomach is impaired, e.g. by cancer, a vitamin B12 deficiency can result.
The symptoms are sometimes very nonspecific and can also occur with other diseases. It is therefore important to see a doctor if you notice any signs.
When is stomach cancer treated?
The diagnosis of stomach cancer is confirmed by an upper endoscopy (gastroscopy) with removal of tissue samples (biopsies). In addition, further examinations are carried out (e.g. computed tomography) to determine how far the disease has already progressed. Certain features are also determined in the tumor tissue (e.g. HER2, PD-L1, microsatellite instability, Claudin 18.2), because they determine which drugs will work. Treatment depends on the stage of the cancer and other factors and is tailored individually with each patient.
How is stomach cancer treated?
Treatment depends on the stage of the disease and other individual factors. Different treatment approaches can be used. These include:
- Endoscopic resection (removal): during the gastroscopy, the cancer is cut out locally; this is an option only in very early stages of cancer.
- Surgical resection: there are various surgical procedures in which usually part of the stomach or the whole stomach is removed together with the surrounding lymph nodes. In most cases, chemotherapy is given before (preoperatively) and after (postoperatively) the surgery.
- Drug therapy for the tumor
- Chemotherapy: various drugs can be used here, usually in combination.
- Immunotherapy and targeted therapy: newer drugs that help the immune system fight the cancer (checkpoint inhibitors), or antibodies against certain features of the cancer cells (e.g. HER2 or Claudin 18.2) – depending on which features the tumor carries.
- Best supportive care: in advanced stages, the main goal is not to cure the cancer but to relieve symptoms and preserve quality of life as well as possible.
How exactly have clinical trials changed the treatment landscape for stomach cancer?
Clinical trials have contributed substantially to improving the treatment of stomach cancer. As recently as around 2000, surgery alone was the main approach. Today, surgery is complemented by drug therapies or, in advanced stages, even replaced by them.
- MAGIC trial: In 2006, the British MAGIC trial showed that chemotherapy before and after surgery markedly improves survival. For this, 503 patients were enrolled in the trial and divided into two groups. In one group, patients only had surgery; in the second group, chemotherapy was combined with surgery. This so-called perioperative chemotherapy, i.e. before and after surgery, is still the standard of care today.
- FLOT4 trial: Which drugs are used for perioperative therapy has changed as a result of further trials. These include the German FLOT4 trial from 2019. It enrolled 716 patients with stomach cancer or cancer at the junction with the esophagus, who were divided into two groups. One group received FLOT chemotherapy, a combination of four active substances. The other group received the standard treatment at the time. It was shown that FLOT chemotherapy prolongs survival (a median of 50 instead of 35 months). FLOT has been the standard in Germany ever since.
- MATTERHORN trial: The MATTERHORN trial is a very recent trial from 2024/2025. It enrolled 948 patients, 474 per group. It was shown that FLOT chemotherapy in combination with the drug durvalumab improves survival even further. Durvalumab is one of the immunotherapies (checkpoint inhibitors).
Clinical trials are continually being conducted to improve treatments. Interested in taking part in clinical trials? Then take a look here at the current trials in Germany.
This information is not a substitute for a conversation with your doctor.
Last updated:
Sources (5)
- Onkopedia-Leitlinie · Magenkarzinom (opens in a new tab)
- Zentrum für Krebsregisterdaten (RKI) · Magenkrebs (opens in a new tab)
- Cunningham D et al.: Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer · N Engl J Med 2006 (opens in a new tab)MAGIC
- Al-Batran SE et al.: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial · Lancet 2019 (opens in a new tab)FLOT4
- Janjigian YY et al.: Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer · N Engl J Med 2025 (opens in a new tab)MATTERHORN